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Background: Cisplatin is one of the most potent chemotherapeutic agents currently in
use for clinical treatment of many types of cancer, including head and neck cancers
(HNCs) and epithelial ovarian cancers (EOCs). Like other platinum agents, it is
thought to function primarily by modifying DNA, forming intrastrand crosslinks and
other DNA lesions. The molecular mechanisms of resistance to cisplatin are not fully
understood, although some forms of resistance have been associated with changes in
DNA Damage Response (DDR). Identification of the new therapeutic targets would
both allow a better understanding of drug resistance mechanisms, and potentially
provide new avenues for disease management.
Methods:We have integrated data from a large number of functional screens
performed in lower eukaryotes for genes conferring resistance to cisplatin and other
DNA damaging agents such as g-ray-, X-ray-, and UV-radiation. We subsequently
identified human orthologues of evolutionary conserved genes that are potentially
involved in DDR and cisplatin sensitivity in humans. We then directly tested the role of
some of these genes in response to the exposure to the DNA damaging agents in EOC
and HNC cell lines. We used small interfering RNAs (siRNAs) to deplete either control
genes or candidate genes of interest, and under basal and drug-treatment conditions,
we assessed cell viability,the impact on phospho-H2AX focus formation, and activation
of the ATR DDR kinase. Besides cisplatin, we assessed gene effect on two additional
DNA damaging drugs, 5-fluorouracil and olaparib.
Results:We identified in silico a set of candidate human genes with yeast orthologs
that are implicated in DDR and regulation of cisplatin sensitivity in Saccharomyces
cerevisiae, developing a novel genomic resource. Depletion of a set of empirically tested
genes sensitized human cancer cells to cisplatin and other DNA damaging drugs, and
affected phospho-H2AX foci and DDR signaling.
Conclusions: Our findings suggest that possible mechanism of sensitization to
cisplatin caused by depletion of these genes involves reduced activation of DDR
responses, and identifies new, non-canonical candidate regulators of DDR based on
evolutionary analysis.
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